Currency fluctuations are a cause for concern for US health care company Abbott Laboratories (NYSE: ABT), as it reports its 2014 figures and looks to 2015.
The European Commission today cleared the sale of Abbott’s developed markets branded generic pharma business to Mylan (Nasdaq: MYL), which is expected to have a positive impact on subsequent earnings.
Sales for the fourth quarter stood at $5.36 billion, a 5.6% increase on the same quarter last year. Abbott's pharmaceutical division generated $922 million of sales, which was a 26.9% increase on the fourth quarter of 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze